When given via various routes (inhalation, intravenous, and subcutaneous), rhu GM-CSF has been reported to improve outcomes for patients who are critically ill, immunocompromised, and suffering from respiratory infection (Table 3) (58–65, 67). The gene discussed is CSF2; the disease is respiratory tract infectious disorder.